Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis

Figure 1 Kaplan–Meier curves of global overall survival and disease-free survival. The median overall survival (OS) and disease-free survival (DFS) were 31 mo [95% confidence interval (CI): 14-53] and 5 mo (95%CI: 1-8), respectively. 1, 3 and 5-yr OS rates were 71.4%, 43.6%, and 7.6%, respectively. 1-, and 3-yr DFS rates were 32.6%, and 16.3%, respectively. A: OS; B: DFS. OS: Overall survival; DFS: Disease-free survival.

Figure 2 Kaplan–Meier curves of overall and disease-free survival comparing the results of the different treatment modalities (P = 0. 312 and P = 0.0001, respectively). Median overall survival (OS) and disease-free survival (DFS) for the resection group were 53 [95% confidence interval (CI): 31-53] and 19 mo (95%CI: 3-Not Evaluable), respectively. Median OS and DFS for the Trans-Arterial ChemoEmbolization group were 18 (95%CI: 8-31) and 0 (95%CI: 0-2) months, respectively. A: OS; B: DFS. OS: Overall survival; DFS: Disease-free survival; TACE: Trans-Arterial ChemoEmbolization.

Figure 3 Kaplan–Meier curves of overall and disease-free survival comparing the results of the different treatment modalities for patients stratified by different parameters (n = 30). A: Stratification by alpha-fetoprotein levels, lower or higher than 400 ng/mL [overall survival (OS): P < 0.0001 and disease-free survival (DFS): P = 0.0001]; B: Stratification by the Up-to-7 criteria, in or out (OS: P = 0.612 and DFS: P =0.002); C: Stratification by the ITA.LI.CA classification (OS: P = 0.047 and DFS: P = 0.001); D: Stratification by the number of lesions, 2 lesions or more than 3 lesions (OS: P = 0.310 and DFS: P = 0.001); E: Stratification by the maximum diameter of the lesion, smaller or bigger than 41 mm (OS: P = 0.215 and DFS: P = 0.001). Median survival is expressed as months and 95% confidence interval. OS: Overall survival; DFS: Disease-free survival; AFP: Alpha-fetoprotein; N.E.: Not Evaluable; TACE: Trans-Arterial ChemoEmbolization.